Aptuit, Inc. announced today that Timothy (Tim) C. Tyson, a 30-year pharmaceutical industry veteran, has been appointed Executive Chairman and acting CEO. Michael A. Griffith, the company’s founder and Chief Executive Officer since 2005, has resigned in order to pursue other opportunities.
“The Board wishes to thank Mike for his outstanding success in creating a world-class organization that is a trusted partner to hundreds of innovative clients throughout the world,” said Tony Ecock, outgoing Chairman of Aptuit’s Board of Managers. “With 2,700 employees working with more than 800 clients throughout the world, Aptuit has established a solid foundation for continued growth and success.”
Aptuit’s interim CEO, Tim Tyson, is the former COO, President and CEO of Valeant Pharmaceuticals International, where he served from 2002-2008. Prior to Valeant, Tyson’s pharmaceutical industry experience includes a 14-year tenure at GlaxoSmithKline, where he was President of Global Manufacturing and Supply and ran Glaxo Dermatology and Cerenex Pharmaceuticals. There he managed all sales and marketing for GlaxoWellcome’s U.S. operations. Tyson has also held executive positions at Bristol-Myers in commercial and technical operations and R&D. Previously he was a manufacturing manager for Procter & Gamble.
“I am honored to have the opportunity to help lead the next phase of Aptuit’s growth, and to build on the many achievements the company has had to date,” Tyson said. “Aptuit is uniquely positioned to help innovative partners create the new medicines of tomorrow, and we will work tirelessly to ensure that we do all that we can to help improve the way drugs are developed.”
About Aptuit
Aptuit, Inc. is a global company focused on streamlining and supporting the drug development process for biotechnology and pharmaceutical innovators. The company was founded by a group of industry experts with extensive market experience who have a track record of building a similar, highly successful company through acquisitions and investment. Aptuit provides a comprehensive suite of product development services and competencies to more than 800 biotechnology and large, fully integrated pharmaceutical innovators worldwide. Aptuit’s mission is to engineer a better drug development process, and is partnered with Welsh, Carson, Anderson & Stowe, one of the world’s largest private equity investors. For more information about Aptuit, please visit www.aptuit.com.
Comments